5GV Stock Overview
Develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.30 |
| 52 Week High | SEK 4.80 |
| 52 Week Low | SEK 1.61 |
| Beta | 1.64 |
| 11 Month Change | 20.66% |
| 3 Month Change | 14.46% |
| 1 Year Change | -41.83% |
| 33 Year Change | -68.39% |
| 5 Year Change | -10.70% |
| Change since IPO | 472.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5GV | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0.2% | -6.1% | -1.3% |
| 1Y | -41.8% | 2.0% | 7.4% |
Return vs Industry: 5GV underperformed the German Life Sciences industry which returned 2% over the past year.
Return vs Market: 5GV underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 5GV volatility | |
|---|---|
| 5GV Average Weekly Movement | 11.8% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5GV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5GV's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Fredrik Olsson | www.genovis.com |
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease.
Genovis AB (publ.) Fundamentals Summary
| 5GV fundamental statistics | |
|---|---|
| Market cap | €159.68m |
| Earnings (TTM) | €2.43m |
| Revenue (TTM) | €11.35m |
65.8x
P/E Ratio14.1x
P/S RatioIs 5GV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5GV income statement (TTM) | |
|---|---|
| Revenue | SEK 130.57m |
| Cost of Revenue | SEK 15.13m |
| Gross Profit | SEK 115.44m |
| Other Expenses | SEK 87.53m |
| Earnings | SEK 27.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 0.43 |
| Gross Margin | 88.41% |
| Net Profit Margin | 21.38% |
| Debt/Equity Ratio | 0% |
How did 5GV perform over the long term?
See historical performance and comparison